Team Members

Sakae Asanuma, CFA, President

Sakae Asanuma established Taiho Ventures as the founding President in 2016. Prior to joining Taiho, he was President and CEO at Astellas Venture Management and US Head of Astellas Innovation Management in 2011-2015. Prior to Astellas, he worked for Yasuda Enterprise, a Japan/US-based VC firm in 2000-2011. He has invested in more than 50 biotech companies since 2000 and half of them achieved IPOs or M&As. During his days at Taiho and Astellas, he closed dozens of research collaborations with academia and biotech ventures, including several build-to-buy or spin-out deals.

Seiji Miyahara, PhD, Investment Director

Seiji Miyahara joined Taiho Ventures in 2016. He is mainly responsible for investment identifications, due diligence, new company creation, open innovation support and portfolio support. Prior to joining Taiho Ventures, he worked at Taiho Pharmaceutical for 12 years as a chemistry project leader in oncology field, where he was involved in the development of first-in-class dUTPase/DPD dual inhibitor (TAS-114) and a wide range of oncology drug discovery programs. He received his PhD in life science from Hokkaido University.

SHINICHI HASAKO, PHD, INVESTMENT DIRECTOR

Shinichi Hasako joined Taiho Ventures in 2019. His background is in tumor cell biology and research and development of anti-cancer drug. He worked at Taiho Pharmaceutical as a biology leader of a kinase inhibitor project targeting EGFR exon 20 insertion mutation, and his team identified TAS6417. He was continuously responsible for the preclinical studies and clinical development strategy of the molecule as the Product Chair. Besides that, he was involved in biomarker development of Taiho's preclinical and clinical pipelines. He received his PhD in disease mechanism of lung cancer from Tsukuba University.

TAKAAKI ISHII, ASSOCIATE INVESTMENT DIRECTOR

Takaaki Ishii, a molecular biologist by training, joined Taiho Ventures in 2019. He has acquired over 11 years of oncology expertise in early stage clinical development, product portfolio strategies as well as scientific evaluations for in-house and potential partnering programs in a wide range of cancer types. His representative contribution to Taiho Pharmaceutical includes in-licensing AB928 (A2aR/A2bR Dual Antagonist) from Arcus Biosciences as well as both medical and Medical Science Liaison activities for nab-paclitaxel (ABRAXANE®) and pembrolizumab (KEYTRUDA®) in Japan.